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Background. Measles-mumps-rubella (MMR) vaccinations have been offered to Finnish children at 14–18 months and 6 years
of age. In May 2011, the recommended age for the ﬁrst vaccine dose was lowered to 12 months because of the European measles
epidemic.
Methods. Fingertip capillary blood samples were collected from 3-year-old Finnish children vaccinated once with MMR vaccine
at 11–19 months of age. The immunoglobulin G (IgG) antibodies to all 3 MMR antigens were measured with enzyme-linked im-
munosorbent assay. Neutralizing antibodies and the avidity of antibodies were measured for measles virus.
Results. From April through October 2013, 187 children were enrolled. Equally high proportions of the samples were seropos-
itive for measles virus, mumps virus, or rubella virus antibodies, and there were no signiﬁcant differences in the IgG antibody con-
centrations in children vaccinated at 11–13 months of age, compared with those vaccinated at 17–19 months of age. However, among
children vaccinated at 11–13 months of age, boys had lower antibody concentrations than girls. Neutralizing measles virus antibody
titers were above the threshold for protective immunity in all 78 samples analyzed. The measles virus antibody avidity indexes were
high for all children.
Conclusions. MMR induces similar antibody responses in 12-month-old children as compared to 18-month-old children, but in
boys increasing age appears to improve the antibody responses.
Keywords. MMR; measles; mumps; rubella; vaccine; antibody; immune response; immunization; vaccination schedule.
Measles-mumps-rubella (MMR) vaccinations were included in
Finland’s national immunization program in 1982 with a 2-
dose vaccine schedule, in which the ﬁrst dose was recommend-
ed to be given at 14–18 months of age and the second at 6 years
of age. Measles vaccine was ﬁrst introduced in 1975, adminis-
tered at the age of 14 months. As a result of consistently high
vaccination coverage (>95%) since 1987, endemic diseases
targeted by MMR were eliminated by 1995 [1]. Since the elim-
ination, only 1–5 imported measles cases have been reported
annually. Although MMR vaccines have been available in
most European countries for >30 years, measles and rubella ep-
idemics still occur, mostly among unvaccinated populations [2].
The number of European measles cases reached a new peak in
2011, when >30 000 measles cases in 29 countries were reported
to the European Centre for Disease Prevention and Control [3].
In the same year, an increased number of measles cases (n = 27)
was also reported in Finland [4].
The recommended age for the ﬁrst MMR vaccination in Eu-
rope varies from 9 to 18 months, according to the national pro-
grams in different countries. The optimal timing for the ﬁrst
MMR vaccination would be as soon as the child’s immune system
is mature enough to effectively respond to the vaccine and when
maternal antibodies have waned and no longer interfere with the
vaccine response. Previous studies have reported that if the ﬁrst
dose of MMR vaccine was given before or at the age of 11 months,
the proportion of children producing antibodies was lower [5–7],
the vaccine induced a lower antibody response [8, 9], and the ef-
ﬁcacy of the vaccine was inferior [10], compared with ﬁndings for
children who received the vaccine at the age of ≥12 months.
It is known that measles virus infection induces higher anti-
body concentrations than measles vaccine [11] and that the per-
sistence of vaccine-induced antibodies may be shorter than that
for measles vaccine [9, 12–16]. The current vaccine recommen-
dations are mostly based on data derived from the prevaccine
era, when the mothers of the study children frequently had
anti–measles virus antibodies induced by natural measles
virus infection. In many developed countries, including Fin-
land, where MMR vaccines have been included in the national
immunization program for 3 decades, with high vaccination
coverage, a large proportion of the women of childbearing age
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have antibodies to measles virus induced by vaccination, not by
natural infection.
In May 2011, the National Institute for Health andWelfare in
Finland lowered the recommended age from 14 to 18 months to
12 months because of measles outbreaks in Europe. Previously,
the ﬁrst dose of the MMR vaccine was most commonly admin-
istered at 18 months of age at a regular visit to a child healthcare
clinic. The main aim of this observational study was to investi-
gate whether differences exist in the levels of antibodies induced
by the MMR vaccine, especially those against measles virus, in
children vaccinated at the age of 12 months (range, 11–13
months) and 18 months (range, 17–19 months).
MATERIALS AND METHODS
Study Group
Children born from November 2009 through October 2010 were
recruited to the study from 2 cities in Finland (Helsinki and Tam-
pere) in 2 phases; from April to June 2013 and from August to
October 2013. Inclusion criteria were age of 34–44 months, re-
ceipt of 1 dose of the MMR vaccine between the ages of 11
and 20 months, understanding of Finnish by at least one of the
child’s parents, and parental written informed consent. Exclusion
criteria were fever (temperature, ≥38°C) within 72 hours before
sample collection, receipt of immunosuppressive treatment after
MMR vaccination, and a history of measles virus infection. The
parents of the participants completed a questionnaire on the vac-
cination history (validated from the vaccination certiﬁcate of the
child) and medical history of the child, as well as birth year and
medical history of the parents. The study protocol has received a
favorable opinion from the ethics committee for gynecology and
obstetrics, pediatrics, and psychiatry of the Helsinki and Uusimaa
Hospital District (198/13/03/2012). The vaccination history of
the children participating in the study was conﬁrmed from the
national vaccination registry (THL/823/6.0200/2014). The M-
M-RVaxPro vaccine (Sanoﬁ Pasteur MSD), which contains the
Edmonston strain of measles virus, the Jeryl Lynn strain of
mumps virus, and the Wistar RA27/3 strain of rubella virus,
was the MMR vaccine used in the national immunization pro-
gram from May 2010 to March 2012.
Sample Collection
Capillary blood samples were collected by making a small inci-
sion to the ﬁngertip with a lancet and by drawing a volume of
500 µL to 1 mL of blood into a microtube containing gel for
serum extraction. The blood samples were kept at room temper-
ature for 30 minutes, after which serum was separated by cen-
trifugation for 1 minute 30 seconds at 10 000g. The serum
samples were stored at −20°C.
Measurement of Immunoglobulin G (IgG) Concentrations With an
Enzyme-Linked Immunosorbent Assay (ELISA)
IgG antibodies to the measles virus, mumps virus, and rubella
virus strains in the MMR vaccine were measured by using
commercial ELISAs (Enzygnost, Siemens, Germany) according
to the manufacturer’s instructions. The quantitative cutoff was
≥150 mIU/mL for measles virus IgG, a titer of ≥230 for mumps
virus IgG, and ≥4 IU/mL for rubella virus IgG, as determined
by the manufacturer. Values equal to half of the concentration
of the cutoff were assigned to samples containing antibody con-
centrations lower than the cutoff. Seropositivity was deﬁned as
an antibody concentration of ≥325 mIU/mL to measles virus, a
titer of ≥ 570 for mumps virus, and a concentration of ≥7 IU/
mL for rubella virus. Samples with equivocal IgG ﬁndings were
not considered seropositive. This more stringent deﬁnition of
seropositivity was used to compare the proportions of seropos-
itive samples in children vaccinated at the age of 11–13 or 17–19
months. Protective-threshold ELISA values for IgG to measles,
mumps, and rubella viruses have not been established.
Avidity Determination of IgG Antibodies Against Measles Virus
The avidity of measles virus antibodies was measured with the
Euroimmun ELISA kit (Lübeck, Germany) according to the
manufacturer’s instructions. The relative avidity index was cal-
culated as a percentage ([OD of urea-treated specimen]/[OD of
untreated specimen] × 100]. Avidity index values of <40% were
considered to indicate low avidity, values of 40%–60% indicated
intermediate avidity, and values of >60% indicated high avidity
of the antibodies in a sample.
Plaque Reduction Neutralization Test (PRNT) for Anti–Measles Virus
Antibodies
The functional activity of anti–measles virus antibodies was mea-
sured using a modiﬁed plaque reduction neutralization test
(PRNT) [17], with four-fold dilutions of sera in duplicate from
1:2 to 1:128 dilutions. In short, sera were mixed with an equal
volume of the deﬁned amount (20–30) vaccine virus (genotype
A) and incubated for 1 hour at +36°C and 5% CO2. The mixture
was incubated on 24-well plates (Falcon) with VeroSLAM cells
(Robert Koch institute/WHO) at +36°C and 5% CO2 for 30 min-
utes. Agarose with 1x DMEM (Dulbecco’s Modiﬁed Eagle Medi-
um) and 4% fetal bovine serum was added to the wells and the
plates were incubated for 6 days at +36°C and 5%CO2. The plates
were ﬁxed with 30% Formalin and stained with crystal violet. The
assay was standardized using the 3rd World Health Organization
International Standard for Anti-Measles (National Institute for
Biological Standards and Control code 97/648). An antibody
concentration of ≥120 mIU/mL was considered protective [18].
Samples that had a neutralizing antibody titer higher than what
could be accurately determined with the highest sample dilution
used in the analysis were assigned a value of 1500 mIU/mL.
Statistical Analysis
The primary hypothesis of the study was that the log-
transformed antibody concentrations to MMR vaccine antigens
are similar in children vaccinated at 12 or 18 months of age.
Based on the sample size calculation, we estimated that at least
70 participants (equal proportions of children vaccinated at 12
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and 18 months) would be required to detect a 35% difference in
geometric mean titers between the 2 independent groups, with a
statistical power of 80% and signiﬁcance level (α) of 0.05, assum-
ing equal relative variability coefﬁcient of variation (0.7) in both
groups [19]. Statistical analyses were performed using antibody
concentrations and titers after logarithmic transformation. The
geometric mean concentrations and mean avidities of IgG anti-
bodies were compared with unpaired, 2-tailed Student t tests, as-
suming unequal variances. Pearson correlation was calculated for
comparison of the association between the concentration and
avidity of anti–measles virus antibodies. Pearson correlation
was also used for comparison of age at immunization and con-
centration of IgG antibodies to MMR vaccine antigens or avidity
of anti–measles virus antibodies. Scatterplots and curves for age
and IgG concentration or avidity index were calculated by using
locally weighted scatterplot smoothing. Statistical data were
analyzed with Prism 5 (GraphPad, San Diego, California) and
QuickCalcs GraphPad Software (for the Fisher exact test). P
values of <.05 were considered statistically signiﬁcant.
RESULTS
Proﬁle of the Study Population
Overall, 187 children (97 boys and 90 girls) were enrolled, and
all had received 1 dose of M-M-RVaxPro. The majority of the
children had been immunized at the age of 11–13 months or
17–19 months (Table 1 and Figure 1). Boys were similar to
girls in regard to age at immunization, time from immunization
to blood sample collection, and age at blood sample collection
(Table 1). The mean age of the children was 3 years, 3 months at
the time of blood sample collection, and the mean interval be-
tween immunization and blood sample collection was 2 years
(Figure 1). Of the 181 of 187 mothers who reported their birth-
day and history of measles virus infection, 48 were born before
1975, the year when measles vaccine was introduced in the
Finnish immunization program, and 92 were born after 1974
but before 1982, when MMR vaccine was introduced. None of
the 41 mothers born after 1981 reported a history of measles
virus infection, but 5 of 92 mothers born in 1975–1981 and
14 of 48 born before 1975 (11 of 37 born before 1974) reported
having had measles.
Seropositivity to MMR Antigens
All 187 serum samples contained detectable antibodies to
rubella virus (>4 IU/mL); all but 2 samples had antibodies
to measles virus (≥150 mIU/mL), but in as many as 29 sam-
ples (16%) anti–mumps virus antibodies were below the
limit of detection (titer <231). Equally high proportions of
the children immunized at the age of 11–13 months and at
Table 1. Antibodies to Measles, Mumps and Rubella in Children Immunized at the Age of 11 to 19 Months
Characteristic
Age at Immunization
P Valuea11–13 mo 14–16 mo 17–19 mo
Age at immunization, mo, mean ± SD
Overall 12.4 ± 0.4 15.2 ± 0.9 18.3 ± 0.6
Among boys 12.4 ± 0.5 15.0 ± 0.8 18.4 ± 0.6
Among girls 12.4 ± 0.4 15.4 ± 0.9 18.3 ± 0.7
Participating children, no.
Overall 85 32 70
Boys 42 15 40
Girls 43 17 30
Age at blood sample collection, mo, mean ± SD
Overall 37 ± 1.6 39 ± 1.8 40 ± 1.5 NS
Among boys 37 ± 1.8 39 ± 1.8 40 ± 1.5 NS
Among girls 37 ± 1.5 39 ± 1.8 40 ± 1.5 NS
Interval from immunization to blood sample collection, mo, mean ±SD
Overall 25 ± 1.6 24 ± 1.7 22 ± 1.6
Among boys 25 ± 1.8 24 ± 1.9 22 ± 1.5 NS
Among girls 25 ± 1.4 23 ± 1.4 22 ± 1.7 NS
Anti–measles virus IgG GMC (95% CI) 2436 (1894–3134) 2835 (1990–4038) 2772 (2150–3574) NS
Anti–mumps virus IgG GMT (95% CI) 942 (731–1214) 811 (505–1301) 817 (619–1078) NS
Anti–rubella virus IgG GMC (95% CI) 59 (50–70) 57 (44–74) 73 (60–88) NS
Anti–measles virus IgG avidity index, %, mean ± SD 91± 5.8b 93 ± 5.0 94 ± 6.0 .0054
Anti–measles virus PRNT-based GMC (95% CI) 887 (715–1100)c NA 1180 (1001–1391)d NS
Abbreviations: CI, confidence interval; GMC, geometric mean concentration; GMT, geometric mean titer; IgG, immunoglobulin G; NA, not available; NS, not significant; PRNT, plaque reduction
neutralization titer; SD, standard deviation.
a By the unpaired Student t test (assuming unequal variances) for comparison of data from children aged 11–13 months to data from children aged 17–19 months.
b Measured in samples from 84 of 85 children immunized at 11–13 months of age.
c Measured in samples from 40 children immunized at 11.6–12.3 months of age.
d Measured in samples from 38 children immunized at 17.3–18.5 months of age.
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17–19 months had detectable antibodies to measles virus
(98% vs 97%), rubella virus (100%), or mumps virus (89%
vs 81%; P = NS, by the Fisher exact test). The proportions
of seropositive antibody concentrations to measles virus
(≥325 mIU/mL), mumps virus (titer ≥570), and rubella
virus (≥7 IU/mL) were also similar in children immunized
with MMR vaccine at the age of 11–13, 14–16, or 17–19
months (Figure 2).
IgG Antibody Concentrations to MMR Vaccine Antigens
The geometric mean IgG antibody concentrations to measles,
mumps, and rubella viruses measured with ELISA were similar
in children immunized at the age of 11–13, 14–16, or 17–19
months (Figure 3 and Table 1). No signiﬁcant differences (based
on the unpaired Student t test, assuming unequal variances) were
seen in geometric mean IgG concentrations to any of the MMR
vaccine antigens between children immunized at 11–13 and 17–
19 months of age. The geometric mean concentrations of antibody
to measles virus were similar in children born to mothers with a
self-reported history of measles (2834 mIU/mL; n = 20; 13 boys)
and in children whose mothers did not report having had measles
(2514 mIU/mL; n = 167; 83 boys). The mean age of the children
was 15 months in both groups. No association was seen between
the age at immunization and the concentration of antibodies to
measles, mumps, or rubella virus (Figure 5).
Avidity of Anti–Measles Virus IgG Antibodies
All serum samples had high-avidity (avidity index, >60%) anti–
measles virus antibodies (Table 1 and Figure 4A). The mean avid-
ity index of children immunized at 17–19 months of age was
slightly higher than that in children immunized at 11–13 months
of age (94% vs 91%; Table 1 and Figure 4A). A signiﬁcant positive
correlation was observed between the avidity and the concentra-
tion of anti–measles virus IgG antibodies (r = 0.52; P < .0001, by
Pearson correlation). A weak but statistically signiﬁcant positive
correlation was observed between increasing age at immunization
and avidity of anti–measles virus antibodies (r = 0.21; P < .005, by
Pearson correlation; Figure 5).
Neutralizing Anti–Measles Virus Antibodies
All tested samples of the children immunized at the age of 12 or
18 months had neutralizing anti–measles virus antibodies above
Figure 1. A, The majority of the children recruited to the study during spring 2013
had received their first dose of the measles-mumps-rubella (MMR) vaccine accord-
ing to the old vaccination recommendation, at around the age of 18 months, whereas
most children recruited to the study in fall 2013 had been immunized at the age of 12
months, according to the new vaccination recommendation. B, Children immunized
at the age of 11–13 months were on average 3 months older at the time of blood
sample collection. C, The interval between immunization and blood sample collec-
tion was on average 3 months longer for children immunized at the age of 11–13
months, compared with children immunized at the age of 17–19 months.
Figure 2. The proportions of seropositive samples at the age of 3 years were sim-
ilar in children immunized with measles-mumps-rubella (MMR) vaccine at the age of
11–13 months (n = 85), 14–16 months (n = 32), or 17–19 months (n = 70). P = not sig-
nificant, by the Fisher exact test. The cutoffs for seropositivity were a concentration
of ≥325 mIU/mL for anti–measles virus antibody (Ab), a titer of ≥570 for anti–
mumps virus Ab, and a concentration of ≥7 IU/mL for anti–rubella virus Ab.
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the threshold considered to indicate protective immunity
(PRNT titer, >120 mIU/mL). The PRNT-based geometric
mean titer was similar in children immunized at 12 months
(887 mIU/mL) and in children immunized at 18 months
(1180 mIU/mL; Table 1 and Figure 4B).
Effect of Sex on the Antibody Concentrations
The serum concentrations of IgG against measles, mumps, and
rubella viruses were signiﬁcantly higher in girls as compared to
boys immunized at 11–13 months of age but not in those
immunized at 17–19 months of age (Figure 6). The geometric
mean IgG concentrations in girls as compared to boys
immunized at 11–13 months of age were 2-fold for measles
virus (3450 mIU/mL vs 1720 mIU/mL) and mumps virus
(1330 mIU/mL vs 660 mIU/mL) and 1.5-fold for rubella
virus (73 vs 47 IU/mL). A trend of positive correlation was
seen in boys but not girls between increasing age at immuni-
zation and a higher concentration of IgG antibodies to measles
virus (r = 0.23; P = .024, by Pearson correlation) and rubella
virus (r = 0.20; P = .002) and a higher avidity of anti–measles
virus antibodies (r = 0.28; P = .005). The proportions of sam-
ples seropositive for anti–measles virus, anti–mumps virus,
and anti–rubella virus were similar in 11–13-month-old
boys, compared with those in girls (P = not signiﬁcant, by
the Fisher exact test). The mean avidity index of anti–measles
virus antibodies was equally high (>90%) in girls and boys im-
munized at 11–13 months or 17–19 months of age. The geo-
metric mean concentration of neutralizing anti–measles virus
antibodies was lower in boys immunized at 12 months (648
mIU/mL), compared with boys immunized at 18 months
Figure 3. Anti–measles virus (A), anti–mumps virus (B), and anti–rubella virus (C)
immunoglobulin G (IgG) antibody levels measured by an enzyme immunoassay in
serum samples from 3-year-old children immunized with measles-mumps-rubella
(MMR) vaccine at the age of 11–19 months. No statistically significant differences
were detected by 1-way analysis of variance in the geometric mean IgG antibody
concentrations between children immunized at 11–13, 14–16, and 17–19 months
of age.
Figure 4. Avidity of anti–measles virus immunoglobulin G (IgG) antibodies (A) and
neutralizing measles virus antibody titers determined by the plaque reduction neu-
tralization test (PRNT; B) in 3-year-old children immunized at 12 or 18 months of age.
An avidity index of >60% indicates high avidity of anti–measles virus antibodies, and
a PRNT-based titer of >120 mIU/mL (dashed line) indicates the threshold for protec-
tive antibody level. The avidity of anti–measles virus antibodies was measured in
children immunized at the age of 11–13 months (n = 84) or 17–19 months (n = 70);
mean avidity indexes are indicated with vertical lines. Neutralizing antibody titers
were measured in children immunized at the age of 12 months (n = 40) or 18 months
(n = 38). The mean avidity indexes and geometric mean neutralizing antibody titers
are indicated with vertical lines. **P < .01, by an unpaired, 2-tailed Student t test,
assuming unequal variances.
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(1270 mIU/mL) and with girls immunized at 12 months
(1200 mIU/mL; Figure 6).
DISCUSSION
In this study, we report persistence of high antibody concentra-
tions toMMR vaccine antigens in 3-year old children immunized
with 1 dose of the vaccine at 12 or 18 months of age. The con-
centrations of IgG antibodies to the MMR vaccine components
were equally high in children immunized at the age of 12 or 18
months, yet we detected lower concentrations in boys immunized
at 12 months. All children had high-avidity IgG antibodies. Lev-
els of neutralizing antibodies were above the protective threshold
for measles virus in all children, although the quantitative results
were lower for boys immunized at 12 months.
Previous studies have indicated that vaccination at an older age
tends to increase the antibody response to measles virus [20–23].
A positive linear relationship between age at immunization and
anti–measles virus antibody titer was seen in 4–16-year-old Ca-
nadian children [24]. Reduced immune responses to measles
virus in children younger than 6 months have been explained
on the basis of the immaturity of the immune system [20, 25]
and the presence of maternally derived anti–measles virus anti-
bodies that interfere and weaken the immune response [26, 27].
Previous ﬁndings by Gans et al and Nair et al indicate that the
capacity of the immune system to generate humoral responses
to measles vaccine is impaired in 6-month-old infants even in
the absence of maternal antibodies, suggesting immaturity of
B-cell function, while (in the absence of maternal antibodies)
the humoral response to the vaccine in 9-month-old infants is
equivalent to that in 12-month-old infants [21–23]. De Serres
et al reported that, during a measles outbreak in Canada in
2011, the number of measles cases observed among teenaged
Figure 5. Scatterplot and curves for age at immunization and concentration of immunoglobulin G (IgG) antibodies to measles virus (A), mumps virus (B), and rubella virus (C)
and avidity of antibodies to measles virus (D) in 3-year-old children (n = 187) immunized between the age of 11 and 20 months. The curves were calculated by using locally
weighted scatterplot smoothing. A statistically significant association was detected by Pearson correlation between age at immunization and avidity of anti–measles virus
antibodies.
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children who had received their ﬁrst MMR vaccine of a 2-dose
schedule at 12 months was higher (38 of 660 children) than
among the children who received their ﬁrst vaccine dose at >15
months (4 of 198 children), resulting in a higher risk ratio for
children ﬁrst vaccinated at 12 months [28]. It was suggested
that interference of maternal antibodies could explain their ob-
servation, because many of the mothers were likely to have en-
countered the wild virus [28], in which case the ﬁnding might
not apply to children born to vaccinated mothers. In countries
such as Finland, where the vaccine coverage has been consistently
high for >3 decades and immunity is not boosted by exposure to
the natural virus, antibody concentrations and avidity wane over
time, even in individuals vaccinated twice with MMR vaccine
[14–16, 29]. The majority of the children in this study were
born to mothers born after 1974 and thus vaccinated, which
means that the maternally received anti–measles virus antibodies
in most of the children studied here have likely been induced by
vaccination. Thus, the data from our study indicate that, in a pop-
ulation with high vaccination coverage, maternally transferred
antibodies do not interfere with the immune response of the chil-
dren if the vaccine is administered at the age of ≥11 months. In
fact, most infants born to vaccinated mothers lack detectable an-
tibodies to measles virus by 6 months of age [29]. The estimated
age at which a child loses the protection by maternal antibodies
and becomes susceptible to measles can be as low as 3.3 months
in highly vaccinated populations [13].
A somewhat surprising secondary ﬁnding of our study was
that the concentrations of antibody against measles, mumps,
and rubella viruses were lower in boys as compared to girls vac-
cinated at 12 months of age. In a comprehensive review article,
Klein et al concluded that clinical data support a role for sex in
the response to viral vaccines [30]. Previous serological studies
have also shown that sex and age at vaccination inﬂuence the im-
mune responsiveness to MMR vaccination. Miller et al reported
that the antibody concentrations to measles virus 4 years after
vaccination were 2-fold higher in girls vaccinated after 14 months
of age, compared with ﬁndings for girls vaccinated before 14
months of age, whereas in boys the antibody concentrations
showed no age effect [31]. Miller et al also found that the anti–
measles virus antibody levels were signiﬁcantly higher (by 1.5-
fold) in girls as compared to boys vaccinated after 14 months
of age [31].Mossong et al found that anti–measles virus antibody
Figure 6. A–C, Anti–measles virus (A), anti–mumps virus (B), and anti–rubella virus (C) immunoglobulin G (IgG) antibody levels measured by an enzyme-linked immuno-
sorbent assay in serum samples from 3-year-old children (82 boys and 70 girls) immunized at the age of 11–13 or 17–19 months. D, Neutralizing anti–measles virus antibody
levels were measured by the plaque reduction neutralization test (PRNT) in 46 boys and 32 girls immunized at 12 or 18 months of age. Statistically significant differences were
seen in geometric mean antibody concentrations between girls and boys immunized at 11–13 months of age and between boys immunized at 11–13 and 17–19 months of age.
*P < .05, **P < .01, ***P < .001, by the unpaired, 2-tailed Student t test, assuming unequal variances.
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titers in girls were 13% higher than those in boys [24]. In our
study, the mean IgG concentrations to mumps and rubella virus-
es but not measles virus were slightly although not signiﬁcantly
higher in girls as compared to boys also when the children were
immunized at 17–18 months of age. Davidkin et al found that
girls and boys who received their ﬁrst MMR vaccine dose at
the age of 14–18 months had similar antibody levels soon after
the second vaccine dose at the age of 6 years; however, 8 and
15 years after the second dose, the antibody levels to measles
and mumps viruses were signiﬁcantly higher in female vaccines,
compared with male vaccines [12].
Martins et al studied the measles virus–speciﬁc serum antibody
levels of children in Guinea-Bissau before immunization and
found that girls lost maternal anti–measles virus antibodies
more rapidly than boys; at 4.5 months of age, girls were less likely
than boys to have protective maternal antibody levels [32]. Nic-
oara et al, in contrast to Martins et al, observed no signiﬁcant dif-
ferences according to sex in maternal antibody concentrations to
measles, mumps, or rubella virus in Swiss infants [33]. It would be
convenient to hypothesize that, if maternal antibodies wane at an
earlier age in girls than in boys, girls would have less interference
with vaccination than boys of the same age. This could explain the
higher antibody concentrations seen in girls as compared to boys
immunized at 12months of age in this study. However, it is highly
unlikely that the children of this study would have had maternal
antibodies left at the age of 11–13months. Furthermore, we found
that the measles IgG antibody concentrations measured in chil-
dren born to mothers with a self-reported history of measles
were equally high as those in the rest of the study children.
This study was primarily designed to compare the immunogenic-
ity of the MMR vaccine in children immunized at the age of 12 or
18 months. Nevertheless, despite the relatively small sample sizes,
we were able to detect signiﬁcant differences with regard to age at
immunization in the immunogenicity of the MMR vaccine be-
tween sexes. This ﬁnding indicates that the biological differences
associated with sex may affect immune responses to MMR vacci-
nation, even though the mechanisms causing these differences re-
main unexplained.
The main conclusion of our study is that the MMR vaccine
induces high concentrations of high-avidity antibodies to mea-
sles virus, with neutralizing antibody titers well above the pro-
tective threshold in both girls and boys immunized at the age of
12 months. Even though increasing age at immunization ap-
peared to improve the antibody responses in boys, the concen-
tration of neutralizing anti–measles virus antibodies was well
above the protective threshold in all children at the age of 3
years. The immunity to measles, mumps, and rubella will be
further boosted with the second dose of MMR vaccine, given
at the age of 6 years. The potential beneﬁt of better immunoge-
nicity of the ﬁrst vaccine dose when delivered at an older age
should be carefully balanced against the additional risk of
acquiring measles virus infection before children are due to
receive the ﬁrst vaccine dose. As an increasing proportion of
the mothers will have been immunized in childhood, newborns
will have lower maternal antibody levels and are likely to be-
come susceptible earlier. In the current epidemiologic situation,
in which measles epidemics still occur in Europe, MMR vacci-
nation at 12 months instead of 18 months is recommended to
narrow the unprotected window during which maternal anti-
bodies have disappeared and the child does not yet have vac-
cine-induced immunity. Further follow-up investigations,
including analysis of clinical protection, both for vaccine-specif-
ic and nonspeciﬁc outcomes [34], and of potential sex-based
differences, is warranted.
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